Understanding Latin America’s need of self-sufficiency in order to face future pandemics, and with the preservation of life as a priority, we have created VaxThera: a SURA Company expert in the research, development and commercialization of vaccines in Colombia and the region.
MEDELLIN, Colombia, June 30, 2021 /PRNewswire/ -- Understanding Latin America’s need of self-sufficiency in order to face future pandemics, and with the preservation of life as a priority, we have created VaxThera: a SURA Company expert in the research, development and commercialization of vaccines in Colombia and the region. VaxThera advances the development of vaccines for diseases such as COVID-19, Dengue, Yellow Fever and Influenza This company has a projected investment of 54 million dollars made by Seguros SURA Colombia for its first stage, and the knowledge of a group of researchers, led by Dr. Jorge Emilio Osorio Benitez, with more than 30 years of experience in the research and development of vaccines. VaxThera will allow the import and commercialization of vaccines and other types of biological products for Colombia and Latin America, as well as the transfer of technology needed in the country for the production and development of these types of products, thus contributing to health safety for the country and the region. “Several institutions and health experts worldwide, have repeatedly warned that the world must prepare for future pandemics, and be ready to deploy all human, technological and logistics skills in order to protect the population. Aware of this situation, and looking to protect life, Seguros SURA has decided to invest in the creation of VaxThera, because this organization will allow us to move forward in biotechnology, as well as develop and strengthen skills that can turn Colombia into a key agent for Latin America. In SURA, we believe in the importance of research, development and innovation at the service of the people”, stated Juan David Escobar, CEO of Seguros SURA Colombia. VaxThera is a company focused on science, where biologicals will be researched and developed from Colombia for the world, looking to meet Latin America’s need of vaccine production self-reliance, and to guarantee the self-sufficiency of biologicals in the region. The Company is currently developing a universal SARS-CoV-2 vaccine, which is now in its preclinical trial stage in Wisconsin (United States), and is expected to be ready in 2023. This will be a good booster vaccine option, which will facilitate the procurement and distribution processes. Additionally, VaxThera will have the ability to research and produce vaccines against Dengue, Chikungunya, Yellow Fever, Influenza and Zika. While this development comes to fruition, we will move forward with the import of several types of vaccines needed in the region with the help of strategic allies, both for Coronavirus and other types of tropical diseases, in order for the population to be able to have timely access to these medications, and to contribute to Latin America’s health security. “With VaxThera, we will provide an opportunity for Colombia to recover the autonomy to understand, adapt and respond to the needs of the country, taking advantage of highly skilled human talent with valuable ideas. For VaxThera, it is important to build a path that turns Colombia into a country capable of developing, managing and positioning vaccines from their early stages, up to their final development, so that they do not depend on imports. Lastly, this experience in conjunction with Seguros SURA, motivates different sectors to generate alliances, in order to exploit local capacities and infrastructure”, said Jorge Emilio Osorio, CEO of VaxThera. To generate the human, technical and technological abilities needed to allow Colombia to generate independence in terms of biological products, a 35,000 m2 production plant will be built, which will have the highest technological and human talent standards, and which will generate around 500 jobs between all specialty levels. This construction will be finished in 2023, and once operational, it will have the capacity to produce up to 100 million doses per year. VaxThera will represent a sustainable progress in terms of biotechnology and development of specialized skills and human talent, looking to turn Colombia into a key player in research, development and innovation, which translates into technological and biological improvements at the service of the health of Colombians and Latin Americans. Website: www.vaxthera.com Media Resources: Press Kit About VaxThera About Seguros SURA Colombia About Dr. Jorge Emilio Osorio Benítez
View original content to download multimedia:https://www.prnewswire.com/news-releases/vaxthera-a-sura-company-created-in-colombia-for-the-research-and-development-of-vaccines-for-latin-america-301321461.html SOURCE VaxThera |